CROs offering ICH Stability Studies with Antibody-Drug Conjugate (ADC)
9 published
9 published CROs match ICH Stability Studies and Antibody-Drug Conjugate (ADC).
Locations in this set include United States, China, India, United Kingdom, Australia, and Denmark.
Capabilities that show up most often in this set: Analytical Method Development & Validation, In Vitro Pharmacology, In Vivo Efficacy Models, In Vivo PK / PD Studies, and Preclinical In Vitro Studies.
Matching companies
AllucentAllucent is a full-service CRO specializing in clinical development solutions for small and mid-sized biotech companies.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
Oncodesign ServicesContract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/stability-studies/antibody-drug-conjugate.md